Tesamorelin
GHRH analog that stimulates natural growth hormone release, clinically proven to reduce visceral adipose tissue
Tesamorelin (brand name Egrifta) is a synthetic growth hormone-releasing hormone (GHRH) analog. It is FDA-approved for the treatment of HIV-associated lipodystrophy, a condition characterized by excess abdominal fat accumulation in HIV patients on antiretroviral therapy.
Unlike synthetic HGH, tesamorelin works by stimulating the pituitary gland to produce and release growth hormone naturally. This results in a more physiological pattern of GH release, with preserved feedback mechanisms. Clinical trials have demonstrated significant reductions in visceral adipose tissue (VAT) with tesamorelin treatment.
Beyond its approved use, tesamorelin has attracted interest in the anti-aging and body composition optimization communities. Its ability to reduce dangerous visceral fat while maintaining muscle mass makes it particularly appealing for metabolic health optimization.
Primary Benefits
GHRH analog with extended half-life through DAC technology, providing sustained pulsatile GH release over days
Potent synthetic GH secretagogue producing stronger GH release than ipamorelin, with notable cardioprotective properties
Oral GH secretagogue and ghrelin receptor agonist with non-peptide structure enabling once-daily oral dosing